IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v13y2012i5p663-676.html
   My bibliography  Save this article

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Author

Listed:
  • Mehlika Toy
  • Fatih Onder
  • Ramazan Idilman
  • Gokhan Kabacam
  • Jan Richardus
  • Mithat Bozdayi
  • Meral Akdogan
  • Zarife Kuloglu
  • Aydan Kansu
  • Solko Schalm
  • Cihan Yurdaydin

Abstract

In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease. Copyright The Author(s) 2012

Suggested Citation

  • Mehlika Toy & Fatih Onder & Ramazan Idilman & Gokhan Kabacam & Jan Richardus & Mithat Bozdayi & Meral Akdogan & Zarife Kuloglu & Aydan Kansu & Solko Schalm & Cihan Yurdaydin, 2012. "The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 663-676, October.
    • Handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:663-676
    DOI: 10.1007/s10198-012-0413-8
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-012-0413-8
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-012-0413-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Rachael Fleurence & Christopher Hollenbeak, 2007. "Rates and Probabilities in Economic Modelling," PharmacoEconomics, Springer, vol. 25(1), pages 3-6, January.
    2. D. Spackman & David Veenstra, 2008. "A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B," PharmacoEconomics, Springer, vol. 26(11), pages 937-949, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Keith Tolley & Michael Hutchinson & Xiaojun You & Ping Wang & Bjoern Sperling & Ankush Taneja & Mohammed Kashif Siddiqui & Elizabeth Kinter, 2015. "A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-21, June.
    2. Louisa G. Gordon & Elizabeth G. Eakin & Rosalind R. Spence & Christopher Pyke & John Bashford & Christobel Saunders & Sandra C. Hayes, 2020. "Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up," IJERPH, MDPI, vol. 17(22), pages 1-13, November.
    3. Louisa G. Gordon & William Leung & Richard Johns & Bronwen McNoe & Daniel Lindsay & Katharina M. D. Merollini & Thomas M. Elliott & Rachel E. Neale & Catherine M. Olsen & Nirmala Pandeya & David C. Wh, 2022. "Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021," IJERPH, MDPI, vol. 19(6), pages 1-14, March.
    4. Mancy, Rebecca & Prosser, Patrick & Rogers, Simon, 2013. "Discrete and continuous time simulations of spatial ecological processes predict different final population sizes and interspecific competition outcomes," Ecological Modelling, Elsevier, vol. 259(C), pages 50-61.
    5. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    6. Mehlika Toy & David W Hutton & Samuel K So, 2015. "Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-19, November.
    7. Lartey, Stella T. & Si, Lei & Otahal, Petr & de Graaff, Barbara & Boateng, Godfred O. & Biritwum, Richard Berko & Minicuci, Nadia & Kowal, Paul & Magnussen, Costan G. & Palmer, Andrew J., 2020. "Annual transition probabilities of overweight and obesity in older adults: Evidence from World Health Organization Study on global AGEing and adult health," Social Science & Medicine, Elsevier, vol. 247(C).
    8. Anita J Brogan & Sandra E Talbird & James R Thompson & Jeffrey D Miller & Jaime Rubin & Baris Deniz, 2014. "Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-11, March.
    9. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    10. Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus, 2010. "Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder," PharmacoEconomics, Springer, vol. 28(9), pages 751-764, September.
    11. Massimo Bilancia & Giuseppe Pasculli & Danilo Di Bona, 2020. "A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-33, May.
    12. Edmund Jones & David Epstein & Leticia García-Mochón, 2017. "A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models," Medical Decision Making, , vol. 37(7), pages 779-789, October.

    More about this item

    Keywords

    Chronic hepatitis B; Cost-effectiveness analysis; Antiviral therapy; Turkey; Middle income; I18;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:663-676. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.